About Us

Knowledge Meets Curiosity

About CardioReGenix

The World Health Organization (WHO) estimates 17.7 million people die each year from cardiovascular disease (CVD), an estimated 31% of all deaths worldwide. While progress with conventional treatments is making incremental gains, there remains a need to develop innovative therapeutic approaches. Gene therapy has gained significant momentum, mainly for treatment of rare monogenetic diseases, but marketing authorization for gene therapy products has not impacted diseases such as CVD.

Recent deeper understanding of the molecular/cellular mechanisms of CVD, and technology associated with more efficient and safer gene therapy vectors, has allowed new opportunities for development of next generation advanced therapy medicinal products (ATMPs) for CVD.

CardioReGenix focuses on technological innovations for the treatment of CVD, in particular heart failure and myocardial ischemia. We aim to overcome the existing bottlenecks in CVD gene therapy by:

Develop new technology platforms for treatment of CHD and HF by the latest-generation ATMPs

Improve the overall efficacy of ncRNA-based therapeutics for CHD and HF by maximizing delivery and expression in the relevant target cells in the heart

Improve the safety of ncRNA-based therapeutics for CHD and HF by minimizing off-target effects and undesirable immune responses

Conduct preclinical studies in murine and/or porcine models to select the most promising new therapeutic leads for subsequent phase I/II clinical trials

Prepare a first-in-man phase 1 clinical trial with an AAV6-shRNA1212 vector which upregulates endogenous expression of all VEGF-A isoforms in CVD refractory angina patients.

Strengthen EU’s position in GMP-like manufacturing of ATMPs

Our Aim

mauritius images 05285066 scientist using microscope, close up

11062b 2ebb11c6c0244ffd9cdbae37e7134ba3~mv2 (1)

Improving THe Prospect Of gene THrepay

Supported By Robust Preliminary Data

The CardioReGenix project is supported by robust preliminary data and a multi-disciplinary consortium harnessing know-how in vector development, GMP manufacturing, preclinical and clinical cardiology, regulation of ATMP and liaising with EMA, business development and clinical translation. The CardioReGenix project will strengthen Europe's competitive position in gene therapy development for CVD and improve the prospect of a gene therapy successfully treating patients suffering from CVD.